Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background/aim: Hypersensitivity reactions (HSRs) to carboplatin, a key drug for ovarian cancer patients, are problematic. The aim of this study was to evaluate the efficacy and safety of readministration of platinum agents (PTs) in recurrent ovarian cancer patients who developed HSRs to carboplatin.
Patients And Methods: Thirty-one patients with recurrent ovarian cancer who developed HSRs to carboplatin were divided into those who continued to receive PTs in the following cycle (continuation group, n=24) and those in whom either the drug was switched to non-platinum agents (non-PTs) or chemotherapy was ended (discontinuation group, n=7). Outcomes were evaluated based on patients' medical records.
Results: The median survival time following HSRs was 28.1 and 15.4 months in the continuation and discontinuation groups, respectively (p=0.018). In the continuation group, a total of 155 cycles of PTs were re-administrated, and 50 cycles (32%) led to recurrent HSRs. There were no recurrent HSRs with a severity of grade 3 or greater.
Conclusion: Continuation of PTs in ovarian cancer patients may contribute to improvement in their overall survival without severe recurrent HSRs.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6899094 | PMC |
| http://dx.doi.org/10.21873/invivo.11702 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Advances in Systemic Therapy for Ovarian Cancer Over the Past Decade: A Clinical and Molecular Perspective.
Med Sci Monit
August 2025
Independent Laboratory of Translational Medicine, Medical University of Lublin, Lublin, Poland.
Epithelial ovarian cancer (EOC) remains a leading cause of gynecologic cancer mortality, with high rates of recurrence and chemoresistance. Advances in understanding the molecular biology of EOC, particularly BRCA mutations and homologous recombination deficiency (HRD), have led to more targeted therapies. This review provides an updated summary of systemic treatments for EOC, with an emphasis on personalized therapy approaches and emerging therapeutic strategies.
View Article and Find Full Text PDFClinical value of preoperative serum calcium level in predicting deep infiltrative endometriosis among ovarian endometrioma.
Ann Med
December 2025
Department of Gynecology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong Province, China.
Objective: To evaluate preoperative serum calcium levels and their association with deep infiltrating endometriosis (DIE) in ovarian endometrioma.
Design: A retrospective, observational cohort study.
Participants: A total of 2,557 women who underwent surgery for benign ovarian tumors were initially enrolled.
The Promising Role of PKM2 in the Diagnosis and Prognosis of Ovarian Cancer.
Anticancer Agents Med Chem
September 2025
Department of Pharmaceutical Chemistry, Maharana Pratap College of Pharmacy, Kanpur-209217, Uttar Pradesh, India.
PKM2 has emerged as a critical biomarker with the potential to enhance both diagnostic accuracy and therapeutic strategies in ovarian cancer. Due to its high fatality rate and difficulty identifying early signs, ovarian cancer remains a major global health concern. Biomarkers, particularly PKM2, provide targeted therapeutic methods and early detection.
View Article and Find Full Text PDFMirvetuximab soravtansine in the ovarian cancer treatment landscape: influence of prior taxane exposure on outcomes.
Int J Gynecol Cancer
July 2025
University of California, Los Angeles, Department of Gynecologic Oncology, Los Angeles, CA, USA.
Objective: To evaluate prescribing patterns, toxicities, and outcomes among patients receiving mirvetuximab for platinum-resistant ovarian cancer.
Methods: This retrospective study included patients with platinum-resistant ovarian cancer with high folate receptor alpha expression treated with mirvetuximab at a single institution (2018-2023). Patients were categorized based on treatment immediately preceding mirvetuximab: the taxane group received taxane treatment; the non-taxane group received other therapy.
Hyperthermic intraperitoneal chemotherapy (HIPEC) for primary advanced-stage or recurrent ovarian cancer: A systematic review and meta-analysis of randomized control trials.
Eur J Surg Oncol
September 2025
Hospital Federal dos Servidores do Estado, Rio de Janeiro, Brazil. Electronic address:
Background: Ovarian cancer has the highest mortality among gynecologic malignancies. Despite cytoreductive surgery (CRS) and systemic therapy, peritoneal recurrence remains common. Hyperthermic intraperitoneal chemotherapy (HIPEC) delivers heated chemotherapy directly to the peritoneal cavity, enhancing local cytotoxicity and offering a potential therapeutic strategy.
View Article and Find Full Text PDF